Morgan Stanley Purple Biotech Ltd. Transaction History
Morgan Stanley
- $1.27 Trillion
- Q2 2024
A detailed history of Morgan Stanley transactions in Purple Biotech Ltd. stock. As of the latest transaction made, Morgan Stanley holds 203,000 shares of PPBT stock, worth $1.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
203,000
Previous 136,610
48.6%
Holding current value
$1.1 Million
Previous $91,000
8.79%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding PPBT
# of Institutions
23Shares Held
1.91MCall Options Held
5.6KPut Options Held
0-
Armistice Capital, LLC New York, NY1.36MShares$7.33 Million0.01% of portfolio
-
Kingswood Wealth Advisors, LLC San Diego, CA208KShares$1.12 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il24.6KShares$132,9910.0% of portfolio
-
Venture Visionary Partners LLC22.2KShares$119,6690.0% of portfolio
-
Virtu Financial LLC New York, NY19.3KShares$104,0740.0% of portfolio
About PURPLE BIOTECH LTD.
- Ticker PPBT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,303,300
- Market Cap $98.8M
- Description
- Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhi...